Cargando…
Novel and Potent Dopamine D(2) Receptor Go-Protein Biased Agonists
[Image: see text] The discovery of functionally biased and physiologically beneficial ligands directed toward G-protein coupled receptors (GPCRs) has provided the impetus to design dopamine D(2) receptor (D(2)R) targeted molecules that may be therapeutically advantageous for the treatment of certain...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American
Chemical Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371206/ https://www.ncbi.nlm.nih.gov/pubmed/30775693 http://dx.doi.org/10.1021/acsptsci.8b00060 |
Sumario: | [Image: see text] The discovery of functionally biased and physiologically beneficial ligands directed toward G-protein coupled receptors (GPCRs) has provided the impetus to design dopamine D(2) receptor (D(2)R) targeted molecules that may be therapeutically advantageous for the treatment of certain neuropsychiatric or basal ganglia related disorders. Here we describe the synthesis of a novel series of D(2)R agonists linking the D(2)R unbiased agonist sumanirole with privileged secondary molecular fragments. The resulting ligands demonstrate improved D(2)R affinity and selectivity over sumanirole. Extensive in vitro functional studies and bias factor analysis led to the identification of a novel class of highly potent Go-protein biased full D(2)R agonists with more than 10-fold and 1000-fold bias selectivity toward activation of specific G-protein subtypes and β-arrestin, respectively. Intracellular electrophysiological recordings from midbrain dopamine neurons demonstrated that Go-protein selective agonists can elicit prolonged ligand-induced GIRK activity via D(2)Rs, which may be beneficial in the treatment of dyskinesias associated with dopamine system dysfunction. |
---|